Filing Details
- Accession Number:
- 0001203311-17-000070
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-05 20:23:08
- Reporting Period:
- 2017-08-31
- Accepted Time:
- 2017-09-05 19:23:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1060736 | Seattle Genetics Inc | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1633639 | S Darren Cline | 21823 30Th Drive Se Bothell WA 98021 | Evp, Commercial | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-08-31 | 2,907 | $18.46 | 79,775 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-08-31 | 2,907 | $52.52 | 76,868 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-08-31 | 4,662 | $52.51 | 72,206 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2017-08-31 | 2,907 | $0.00 | 2,907 | $18.46 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2022-02-28 | No | 4 | M | Direct |
Footnotes
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $52.5175 to $52.52. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Shares vested at a rate of 25% on 2/29/2013 and monthly thereafter until all the shares were fully vested on 2/29/2016.